Stockscreener 앱 받기
22.45
5.40%
1.15
시간 외 거래:
22.57
0.12
+0.53%
전일 마감가:
$21.30
열려 있는:
$21.3
하루 거래량:
1.04M
Relative Volume:
1.04
시가총액:
$1.37B
수익:
-
순이익/손실:
$-129.61M
주가수익비율:
-7.5157
EPS:
-2.9871
순현금흐름:
$-116.59M
1주 성능:
+1.04%
1개월 성능:
+32.53%
6개월 성능:
+70.27%
1년 성능:
+114.83%
1일 변동 폭
$21.17
$22.70
1주일 범위
$20.20
$23.12
52주 변동 폭
$6.67
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
명칭
Jade Biosciences Inc
전화
(781) 312-3013
주소
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
22.45 | 1.30B | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 개시 | BTIG Research | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-05-07 | 개시 | Wedbush | Outperform |
| 2025-05-05 | 개시 | Stifel | Buy |
| 2025-05-02 | 개시 | TD Cowen | Buy |
| 2024-06-18 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-03-25 | 재개 | Jefferies | Buy |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-12-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-07-26 | 개시 | Cowen | Outperform |
| 2021-07-26 | 개시 | Evercore ISI | Outperform |
| 2021-07-26 | 개시 | Jefferies | Buy |
| 2021-07-26 | 개시 | Wedbush | Outperform |
모두보기
Jade Biosciences Inc 주식(JBIO)의 최신 뉴스
JBIOJade Biosciences Inc Options - Finviz
Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - Sahm
Jade Biosciences Company Profile & Introduction - Moomoo
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics - marketscreener.com
Jade BiosciencesEnters Exclusive Worldwide License Agreement With Paragon TherapeuticsSEC Filing - TradingView
Jade Biosciences Secures Exclusive Antibody License Agreement - TipRanks
Jade Biosciences Secures Global Exclusive Antibody License From Paragon Therapeutics With Milestones Up to $22M - TradingView
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM:JBIO) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 3000 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 2500 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Form 4 Jade Biosciences Inc For: 26 June By Investing.com - Investing.com India
Jade Biosciences (JBIO) director receives 47,675 stock options at $21.81 strike - Stock Titan
Jade Biosciences (JBIO) director Mark Eisner files initial Form 3 - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Jade Biosciences appoints Mark Eisner to board of directors By Investing.com - Investing.com South Africa
Jade Biosciences appoints Mark Eisner to board of directors - Investing.com
Jade Biosciences Adds Veteran Biopharma Leader to Board - TipRanks
Jade Biosciences Appoints Dr. Mark Eisner to Board, Strengthening Leadership for Autoimmune Therapy Pipeline - Minichart
Jade Biosciences appoints Mark Eisner to its Board and Nominating & Corporate Governance Committee - TradingView
Immunology leader Mark Eisner joins Jade Biosciences (NASDAQ: JBIO) board - Stock Titan
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors - The Manila Times
Jade Biosciences, Inc. Actuals & Estimates (NASDAQ:JBIO) - TradingView
JBIO Forecast — Price Target — Prediction for 2027 - TradingView
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Jade Biosciences Ord Shs (JBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jade Biosciences (JBIO) Surges 5.6% as Biotech Momentum BuildsAAII Neutral - dars.gov.et
UBS Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $45 - Moomoo
UBS Initiates Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $45 - Moomoo
UBS Initiates Jade Biosciences at Buy With $45 Price Target - Moomoo
UBS initiates Jade Biosciences stock at Buy on IgAN drug potential - Investing.com Canada
JBIO Initiated Coverage by UBS -- Price Target Set at $45.00 - GuruFocus
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: Loss Wider Than Expected as Pre-Revenue Biotech Prioritizes Pipeline - newsline.com
Jade Biosciences Shareholders Approve Governance and Audit Measures - TipRanks
[Form 4] Jade Biosciences, Inc. Insider Trading Activity - Stock Titan
Jade Biosciences (JBIO) director granted 34,843 stock options at $15.22 strike price - Stock Titan
Jade Biosciences (JBIO) awards director 34,843 stock options at $15.22 - Stock Titan
Jade Biosciences (JBIO) director Erin Lavelle receives 34,843-share option grant - Stock Titan
Director Kiselak receives 34,843-share Jade Biosciences (JBIO) stock option grant - Stock Titan
Jade Biosciences (NASDAQ: JBIO) holders back charter and bylaw changes - Stock Titan
Fairmount funds lock up 19.99% stake in Jade Biosciences (JBIO) - Stock Titan
Jade Biosciences' JADE101 delivers deep IgA cuts, clearing path for kidney trials - MSN
JBIO Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Faces Investor SkepticismEarnings Trend Analysis - newsline.com
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies - Moomoo
Jade Biosciences closes $172.5m public offering - scanx.trade
Jade Biosciences prices $150M public offering of common stock at $15/share - MSN
Jade Biosciences Inc (JBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):